BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Messiou C, Porta N, Sharma B, Levine D, Koh DM, Boyd K, Pawlyn C, Riddell A, Downey K, Croft J, Morgan V, Stern S, Cheung B, Kyriakou C, Kaczmarek P, Winfield J, Blackledge M, Oyen WJG, Kaiser MF. Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. Radiol Imaging Cancer 2021;3:e210048. [PMID: 34559006 DOI: 10.1148/rycan.2021210048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Barilà G, Crimì F, Arangio Febbo M, Pavan L, Vedovato S, Cabrelle G, Zanon C, Campi C, Cecchin D, Zucchetta P, Lacognata C, Semenzato G, Zambello R. Imaging minimal residual disease evaluation in multiple myeloma using [18F]FDG PET/MRI. Leukemia & Lymphoma 2022. [DOI: 10.1080/10428194.2022.2142053] [Reference Citation Analysis]
2 Santoni A, Simoncelli M, Franceschini M, Ciofini S, Fredducci S, Caroni F, Sammartano V, Bocchia M, Gozzetti A. Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI. J Pers Med 2022;12. [PMID: 36579605 DOI: 10.3390/jpm12111885] [Reference Citation Analysis]
3 Satchwell L, Wedlake L, Greenlay E, Li X, Messiou C, Glocker B, Barwick T, Barfoot T, Doran S, Leach MO, Koh DM, Kaiser M, Winzeck S, Qaiser T, Aboagye E, Rockall A. Development of machine learning support for reading whole body diffusion-weighted MRI (WB-MRI) in myeloma for the detection and quantification of the extent of disease before and after treatment (MALIMAR): protocol for a cross-sectional diagnostic test accuracy study. BMJ Open 2022;12:e067140. [PMID: 36198471 DOI: 10.1136/bmjopen-2022-067140] [Reference Citation Analysis]
4 Rata M, Blackledge M, Scurr E, Winfield J, Koh DM, Dragan A, Candito A, King A, Rennie W, Gaba S, Suresh P, Malcolm P, Davis A, Nilak A, Shah A, Gandhi S, Albrizio M, Drury A, Roberts S, Jenner M, Brown S, Kaiser M, Messiou C. Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma. Insights Imaging 2022;13:123. [PMID: 35900614 DOI: 10.1186/s13244-022-01253-0] [Reference Citation Analysis]
5 Wang Y, Galante JR, Haroon A, Wan S, Afaq A, Payne H, Bomanji J, Adeleke S, Kasivisvanathan V. The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer. Nat Rev Urol 2022. [PMID: 35789204 DOI: 10.1038/s41585-022-00618-w] [Reference Citation Analysis]
6 Giles HV, Wechalekar A, Pratt G. The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: Where are we now and which questions remain unanswered? Br J Haematol 2022. [PMID: 35514140 DOI: 10.1111/bjh.18226] [Reference Citation Analysis]
7 Mesguich C, Hulin C, Latrabe V, Lascaux A, Bordenave L, Hindié E. 18F-FDG PET/CT and MRI in the Management of Multiple Myeloma: A Comparative Review. Front Nucl Med 2022;1. [DOI: 10.3389/fnume.2021.808627] [Cited by in F6Publishing: 1] [Reference Citation Analysis]